Skip to main content
. Author manuscript; available in PMC: 2018 Oct 1.
Published in final edited form as: Clin Cancer Res. 2017 Jul 5;23(19):5836–5845. doi: 10.1158/1078-0432.CCR-16-2862

Figure 2.

Figure 2

A) ADCC results (mean ± SD) of SYD985, T-DM1 (ie, SYD995), Trastuzumab (ie, SYD 997) and ADC isotype control (ie, SYD 989) in two representative HER2 3+ expressing cell lines (ie, SARARK-6: ovary as the primary site and SARARK-9: uterus as the primary site). B) A representative 1+ HER2 expressing cell line (SARARK-7: ovary as the primary site). No significant differences in ADCC between SYD985, T-DM1, or Trastuzumab were detected in CS cell lines with different HER2 expression.